Eiger BioPharmaceuticals (NASDAQ:EIGR) is up 4.9% in relatively light postmarket trading after noting its avexitide treatment got Breakthrough Therapy designation from the FDA, putting it on a fast track.
That comes for the treatment of post-bariatric hypoglycemia, a condition occurring in post-bariatric surgical patients leading to dangerously plow postprandial blood glucose.
The company has seen promising results from a program that’s dosed 54 patients across four Phase 2 studies, it says.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.